State Street SPDR S&P Pharmaceuticals ETF
XPH
85 hedge funds and large institutions have $335M invested in State Street SPDR S&P Pharmaceuticals ETF in 2015 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 26 reducing their positions, and 7 closing their positions.
149% more call options, than puts
Call options by funds: $1.27M | Put options by funds: $511K
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
15% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 26
8% more funds holding
Funds holding: 79 → 85 (+6)
4.38% more ownership
Funds ownership: 57.27% → 61.65% (+4.4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less capital invested
Capital invested by funds: $337M → $335M (-$1.99M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$29.4M |
| 2 |
Morgan Stanley
New York
|
+$3.57M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.74M |
| 4 |
SI
Stephens Inc
Little Rock,
Arkansas
|
+$2.73M |
| 5 |
DC
Davenport & Co
Richmond,
Virginia
|
+$2.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$18.6M |
| 2 |
SG Americas Securities
New York
|
-$4.59M |
| 3 |
NCM
Niemann Capital Management
Stateline,
Nevada
|
-$3.6M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$3.04M |
| 5 |
Jane Street
New York
|
-$2.75M |
XPH Hedge Fund Activity: Q2 2015 in Review
85 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q2 2015, worth a combined $335M — down 0.59% from $337M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new XPH positions and 7 closed out — a net gain of 8 holders — while 30 added to existing stakes and 26 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $29.4M. The largest seller was UBS Group, cutting an estimated $18.6M.
- 85 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q2 2015, up from 79 in Q1 2015.
- Funds reported $335M of State Street SPDR S&P Pharmaceuticals ETF stock for Q2 2015, down 0.59% quarter-over-quarter.
- 15 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q2 2015 and 7 closed out, a net change of +8 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q2 2015 was Goldman Sachs, an estimated $29.4M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q2 2015 was UBS Group, an estimated $18.6M sold.
Based on aggregated 13F filings for Q2 2015.